Uncommon Bio vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Uncommon Bio (formerly Higher Steaks) pivoted from cultivated pork to therapeutic biomanufacturing in 2024–2025; its cultivated meat platform was acquired by Meatable in 2025; now focuses on scalable cell biology tools for human health applications.
About
Uncommon Bio (formerly Higher Steaks) is a UK-based biotechnology company that underwent a significant strategic pivot in 2024–2025, transitioning from cultivated meat production toward developing scalable biomanufacturing technologies for human therapeutic applications. Founded by Benjamina Bollag, the company was originally focused on developing cultivated pork products using cell culture and bioprocess engineering techniques. In 2025, Uncommon Bio's cultivated meat platform and associated intellectual property were acquired by Meatable, a Netherlands-based cultivated meat company — allowing Uncommon Bio to exit the food application space and redirect its biomanufacturing expertise toward the healthcare and therapeutics sector.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.